Data-driven precision: artificial intelligence redefining immunoradiotherapy in advanced pancreatic cancer

Area of Science:

• Oncology
• Artificial Intelligence
• Radiotherapy

Background:

• Advanced pancreatic ductal adenocarcinoma (PDAC) presents significant challenges due to its immunosuppressive tumor microenvironment (TME) and resistance to therapies.
• Current immunoradiotherapy (iRT) approaches show modest benefits in PDAC, limited by heterogeneity and population-averaged treatment paradigms.

Purpose of the Study:

• To develop an artificial intelligence (AI)-enabled framework for refining the biological rationale and clinical application of iRT in advanced PDAC.
• To address inter- and intratumoral heterogeneity through integrative analysis of multimodal data.

Main Methods:

• Integrative analysis of multimodal data, including clinical variables, imaging, RT dose distributions, and multi-omics.
• AI-based deconvolution of TME heterogeneity to identify molecular subtypes and immune architectures.
• AI-driven modeling for optimizing spatiotemporal RT-immunotherapy interactions and predictive response modeling.

Main Results:

• AI can delineate clinically relevant TME subtypes and spatial immune architectures.
• AI models can optimize individualized RT dose, fractionation, and target definition.
• AI supports response-guided treatment adjustments through predictive modeling and adaptive feedback.

Conclusions:

• AI is a catalyst for advancing iRT in PDAC from empirical to precision medicine.
• AI facilitates individualized treatment strategies by addressing heterogeneity and optimizing therapy interactions.
• Further research priorities include prospective digital biobanks, hybrid modeling, and adaptive trial designs for clinical validation.